Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Antiandrogen
100%
Castration-resistant Prostate Cancer
100%
Enzalutamide
100%
Androgen Receptor
42%
Androgen Signaling
28%
Seizure
14%
Placebo
14%
Sigma-1 Receptor
14%
Quality of Life
14%
Diarrhea
14%
Overall Survival
14%
Receptor Binding
14%
Docetaxel
14%
Receptor-mediated
14%
Skeletal-related Events
14%
Hot Flashes
14%
U.S. Food
14%
Previously Treated
14%
Prostate-specific Antigen
14%
Response Time
14%
DNA Transcription
14%
Novel Therapies
14%
Radiographic Progression-free Survival
14%
Pivotal Trial
14%
Soft Tissue Reactions
14%
Response Quality
14%
MDV3100
14%
Oral Inhibitors
14%
Coactivator Recruitment
14%
Astellas
14%
Xtandi
14%
Prostate-specific Antigen Progression
14%
Medicine and Dentistry
Prostate Cancer
100%
Antiandrogen
100%
Enzalutamide
100%
Androgen Receptor
44%
Prostate Specific Antigen
22%
Castration Resistant Prostate Cancer
22%
Epileptic Seizure
11%
Quality of Life
11%
Signal Transduction
11%
Placebo
11%
Diarrhea
11%
Receptor
11%
Androgen
11%
Overall Survival
11%
Progression Free Survival
11%
DNA Transcription
11%
Receptor Binding
11%
Hot Flush
11%
Docetaxel
11%
Tissue Reaction
11%
Oral
11%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Antiandrogen
100%
Enzalutamide
100%
Androgen Receptor
44%
Prostate Specific Antigen
22%
Castration Resistant Prostate Cancer
22%
Receptor
11%
Placebo
11%
Docetaxel
11%
Overall Survival
11%
Preclinical Study
11%
Diarrhea
11%
Androgen
11%
Progression Free Survival
11%
Tissue Reaction
11%
Hot Flush
11%